X

Drug Profile

Research programme: serotonin 1F receptor agonists - Eli Lilly and Company/Lundbeck

Alternative Names: LY 418094

Latest Information Update: 02 Mar 2017

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Eli Lilly and Company; Lundbeck Research USA
Class
Mechanism of Action Serotonin 1F receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Migraine

Most Recent Events

01 Mar 2017 CoLucid Pharmaceuticals has been acquired by Eli Lilly
22 Feb 2006 No development reported - Preclinical for Migraine in USA (unspecified route)
17 Mar 2003 Synaptic Pharmaceutical has been acquired by Lundbeck A/S

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com